Vol 12, No 5 (2011): Practical Diabetology
Review article
Published online: 2011-12-29

open access

Page views 644
Article views/downloads 3912
Get Citation

Connect on Social Media

Connect on Social Media

Bromokryptyna — stary lek w nowej formule skutecznym sposobem leczenia cukrzycy typu 2

Magdalena Pertyńska-Marczewska, Katarzyna Cypryk
Diabetologia Praktyczna 2011;12(5):175-179.


Quick-release bromocriptine mesylate was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes (T2DM). The quick-release formulation of bromocriptine (bromocriptine- QR; Cycloset) represents a novel therapeutic option in T2DM by targeting centrally mediated pathways of glucose metabolism, effecting in reducing plasma glucose, triglycerides, free fatty acid (FFA) levels and eventually cardiovascular events. Randomized controlled trials have shown that bromocriptine- QR lowers glycated hemoglobin by 0.4– –0.8% either as monotherapy or in combination with other anti-diabetes medications. Bromocriptine-QR mechanism of action, unique formulation, clinical efficacy and safety, proves it to be a great alternative to current treatments for type 2 diabetes. (Diabet. Prakt. 2011; 12, 5: 175–179)

Article available in PDF format

View PDF Download PDF file